Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof

A synthetic pediatric formula comprising:

• hydrolyzed protein;
• from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, and lacto-N-fucopentaose;
• vitamin A;
• from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid;
• from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
• wherein the synthetic pediatric formula is shelf stable for at least 3 months.

A synthetic pediatric formula comprising:

• hydrolyzed protein;
• from about 0.01 mg/mL to about 10 mg/mL of at least one of 2′-fucosyllactose, 3-fucosyllactose, 6′-sialyllactose, 3′-sialylactose, and lacto-N-tetraose;
• vitamin A;
• from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid;
• and
• wherein the synthetic pediatric formula is shelf stable from about 3 months to about 24 months.

A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a synthetic pediatric formula comprising:

• hydrolyzed protein;
• from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, and lacto-N-neotetraose;
• vitamin A;
• from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid;
• wherein the docosahexaenoic acid provides less than 1% by weight of the total fat in the synthetic pediatric formula;
• wherein the synthetic pediatric formula is shelf stable for at least 3 months.